Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Tóm tắt
Từ khóa
Tài liệu tham khảo
Adusumilli, 2014, Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity, Sci. Transl. Med., 6, 261ra151, 10.1126/scitranslmed.3010162
Adusumilli, 2019, A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy [abstract]
Alexandrov, 2013, Signatures of mutational processes in human cancer, Nature, 500, 415, 10.1038/nature12477
Ariyan, 2018, Robust antitumor responses result from local chemotherapy and CTLA-4 blockade, Cancer Immunol. Res., 6, 189, 10.1158/2326-6066.CIR-17-0356
Azimi, 2012, Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma, J. Clin. Oncol., 30, 2678, 10.1200/JCO.2011.37.8539
Balachandran, 2017, Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer, Nature, 551, 512, 10.1038/nature24462
Barber, 2006, Restoring function in exhausted CD8 T cells during chronic viral infection, Nature, 439, 682, 10.1038/nature04444
Bauml, 2017, Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study, J. Clin. Oncol., 35, 1542, 10.1200/JCO.2016.70.1524
Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643
Brentjens, 2011, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias, Blood, 118, 4817, 10.1182/blood-2011-04-348540
Brown, 2012, Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T cells, Clin. Cancer Res., 18, 2199, 10.1158/1078-0432.CCR-11-1669
Burga, 2015, Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T, Cancer Immunol. Immunother., 64, 817, 10.1007/s00262-015-1692-6
Caruana, 2015, Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes, Nat. Med., 21, 524, 10.1038/nm.3833
Casey, 2016, MYC regulates the antitumor immune response through CD47 and PD-L1, Science, 352, 227, 10.1126/science.aac9935
Chen, 2017, Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma, J. Clin. Oncol., 35, 2125, 10.1200/JCO.2016.72.1316
Cherkassky, 2016, Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition, J. Clin. Invest., 126, 3130, 10.1172/JCI83092
Chong, 2017, PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR, Blood, 129, 1039, 10.1182/blood-2016-09-738245
Curiel, 2003, Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity, Nat. Med., 9, 562, 10.1038/nm863
Daenen, 2009, Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models, Mol. Cancer Ther., 8, 2872, 10.1158/1535-7163.MCT-09-0583
Danilova, 2016, Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors, Proc. Natl. Acad. Sci. U S A, 113, E7769, 10.1073/pnas.1607836113
Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci. Transl. Med., 6, 224ra225, 10.1126/scitranslmed.3008226
DeSelm, 2018, Low-dose radiation conditioning enables CAR T Cells to mitigate antigen escape, Mol. Ther., 26, 2542, 10.1016/j.ymthe.2018.09.008
Dozier, 2018, Comparative efficacy of T-cell intrinsic versus extrinsic PD-1 blockade to overcome PD-L1+ tumor-mediated exhaustion, J. Thorac. Oncol., 13, S392, 10.1016/j.jtho.2018.08.403
Dunn, 2002, Cancer immunoediting: from immunosurveillance to tumor escape, Nat. Immunol., 3, 991, 10.1038/ni1102-991
El-Khoueiry, 2017, Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial, Lancet, 389, 2492, 10.1016/S0140-6736(17)31046-2
Eroglu, 2018, High response rate to PD-1 blockade in desmoplastic melanomas, Nature, 553, 347, 10.1038/nature25187
Fedorov, 2013, PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses, Sci. Transl. Med., 5, 215ra172, 10.1126/scitranslmed.3006597
Gajewski, 2010, Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy, Cancer J., 16, 399, 10.1097/PPO.0b013e3181eacbd8
Galon, 2006, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313, 1960, 10.1126/science.1129139
Gardner, 2017, Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults, Blood, 129, 3322, 10.1182/blood-2017-02-769208
Gargett, 2016, GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade, Mol. Ther., 24, 1135, 10.1038/mt.2016.63
Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N. Engl. J. Med., 372, 2018, 10.1056/NEJMoa1501824
Gautron, 2017, Fine and predictable tuning of TALEN gene editing targeting for improved T cell adoptive immunotherapy, Mol. Ther. Nucleic Acids, 9, 312, 10.1016/j.omtn.2017.10.005
Geyer, 2016, Review: current clinical applications of chimeric antigen receptor (CAR) modified T cells, Cytotherapy, 18, 1393, 10.1016/j.jcyt.2016.07.003
Heczey, 2017, CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma, Mol. Ther., 25, 2214, 10.1016/j.ymthe.2017.05.012
Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011
Hodi, 2003, Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients, Proc. Natl. Acad. Sci. U S A, 100, 4712, 10.1073/pnas.0830997100
Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N. Engl. J. Med., 363, 711, 10.1056/NEJMoa1003466
Hu, 2019, CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions, Cancer Immunol. Immunother., 68, 365, 10.1007/s00262-018-2281-2
Huang, 2017, T-cell invigoration to tumour burden ratio associated with anti-PD-1 response, Nature, 545, 60, 10.1038/nature22079
Iwai, 2002, Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade, Proc. Natl. Acad. Sci. U S A, 99, 12293, 10.1073/pnas.192461099
John, 2013, Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells, Clin. Cancer Res., 19, 5636, 10.1158/1078-0432.CCR-13-0458
Johnson, 2015, Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma, Sci. Transl. Med., 7, 275ra222, 10.1126/scitranslmed.aaa4963
Joyce, 2015, T cell exclusion, immune privilege, and the tumor microenvironment, Science, 348, 74, 10.1126/science.aaa6204
Kataoka, 2016, Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers, Nature, 534, 402, 10.1038/nature18294
Kleinstiver, 2016, High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects, Nature, 529, 490, 10.1038/nature16526
Kloss, 2013, Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells, Nat. Biotechnol., 31, 71, 10.1038/nbt.2459
Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, Blood, 119, 2709, 10.1182/blood-2011-10-384388
Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, 116, 4099, 10.1182/blood-2010-04-281931
Koneru, 2015, IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo, Oncoimmunology, 4, e994446, 10.4161/2162402X.2014.994446
Koyama, 2016, Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints, Nat. Commun., 7, 10501, 10.1038/ncomms10501
Lamers, 2006, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience, J. Clin. Oncol., 24, 10.1200/JCO.2006.05.9964
Le, 2017, Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733
Leach, 1996, Enhancement of antitumor immunity by CTLA-4 blockade, Science, 271, 1734, 10.1126/science.271.5256.1734
Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3
Li, 2017, Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors, Clin. Cancer Res., 23, 6982, 10.1158/1078-0432.CCR-17-0867
Lipson, 2012, Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody, Clin. Cancer Res., 19, 462, 10.1158/1078-0432.CCR-12-2625
Liu, 2016, A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors, Cancer Res., 76, 1578, 10.1158/0008-5472.CAN-15-2524
Long, 2015, 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nat. Med., 21, 581, 10.1038/nm.3838
Majzner, 2018, Tumor antigen escape from CAR T-cell therapy, Cancer Discov., 8, 1219, 10.1158/2159-8290.CD-18-0442
Marzec, 2008, Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1), Proc. Natl. Acad. Sci. U S A, 105, 20852, 10.1073/pnas.0810958105
Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N. Engl. J. Med., 371, 1507, 10.1056/NEJMoa1407222
McGranahan, 2016, Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science, 351, 1463, 10.1126/science.aaf1490
Melero, 2014, T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy, Cancer Discov., 4, 522, 10.1158/2159-8290.CD-13-0985
Moon, 2011, Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor, Clin. Cancer Res., 17, 4719, 10.1158/1078-0432.CCR-11-0351
Moon, 2014, Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors, Clin. Cancer Res., 20, 4262, 10.1158/1078-0432.CCR-13-2627
Moon, 2018, Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines, Oncoimmunology, 7, e1395997, 10.1080/2162402X.2017.1395997
Morello, 2016, Mesothelin-targeted CARs: driving T cells to solid tumors, Cancer Discov., 6, 133, 10.1158/2159-8290.CD-15-0583
Morgan, 2010, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2, Mol. Ther., 18, 843, 10.1038/mt.2010.24
Moynihan, 2016, Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses, Nat. Med., 22, 1402, 10.1038/nm.4200
Nazareth, 2007, Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells, J. Immunol., 178, 5552, 10.4049/jimmunol.178.9.5552
Nghiem, 2016, PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma, N. Engl. J. Med., 374, 2542, 10.1056/NEJMoa1603702
Obeid, 2016, PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: correlation with tumor-infiltrating immune cells and clinical outcome, Oncoimmunology, 5, e1235107, 10.1080/2162402X.2016.1235107
Odorizzi, 2015, Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells, J. Exp. Med., 212, 1125, 10.1084/jem.20142237
Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, 12, 252, 10.1038/nrc3239
Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia, N. Engl. J. Med., 378, 449, 10.1056/NEJMoa1709919
Parsa, 2007, Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma, Nat. Med., 13, 84, 10.1038/nm1517
Powles, 2014, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 515, 558, 10.1038/nature13904
Rafiq, 2018, Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo, Nat. Biotechnol., 36, 847, 10.1038/nbt.4195
Ren, 2017, Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition, Clin. Cancer Res., 23, 2255, 10.1158/1078-0432.CCR-16-1300
Ribas, 2005, Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206, J. Clin. Oncol., 23, 8968, 10.1200/JCO.2005.01.109
Ribas, 2016, Association of pembrolizumab with tumor response and survival among patients with advanced melanoma, JAMA, 315, 1600, 10.1001/jama.2016.4059
Ribas, 2018, Cancer immunotherapy using checkpoint blockade, Science, 359, 1350, 10.1126/science.aar4060
Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348
Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N. Engl. J. Med., 372, 320, 10.1056/NEJMoa1412082
Robert, 2011, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N. Engl. J. Med., 364, 2517, 10.1056/NEJMoa1104621
Roybal, 2016, Precision tumor recognition by T cells with combinatorial antigen-sensing circuits, Cell, 164, 770, 10.1016/j.cell.2016.01.011
Rupp, 2017, CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells, Sci. Rep., 7, 737, 10.1038/s41598-017-00462-8
Sadelain, 2013, The basic principles of chimeric antigen receptor design, Cancer Discov., 3, 388, 10.1158/2159-8290.CD-12-0548
Sadelain, 2003, Targeting tumours with genetically enhanced T lymphocytes, Nat. Rev. Cancer, 3, 35, 10.1038/nrc971
Sampson, 2014, EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss, Clin. Cancer Res., 20, 972, 10.1158/1078-0432.CCR-13-0709
Savoldo, 2011, CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients, J. Clin. Invest., 121, 1822, 10.1172/JCI46110
Schildberg, 2016, Coinhibitory pathways in the B7-CD28 ligand-receptor family, Immunity, 44, 955, 10.1016/j.immuni.2016.05.002
Schreiber, 2011, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, 331, 1565, 10.1126/science.1203486
Schuberth, 2013, Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells, J. Transl. Med., 11, 187, 10.1186/1479-5876-11-187
Schuster, 2017, Chimeric antigen receptor T cells in refractory B-cell lymphomas, N. Engl. J. Med., 377, 2545, 10.1056/NEJMoa1708566
Schuster, 2015, Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas, Blood, 126, 183, 10.1182/blood.V126.23.183.183
Sharma, 2017, Primary, adaptive, and acquired resistance to cancer immunotherapy, Cell, 168, 707, 10.1016/j.cell.2017.01.017
Slaymaker, 2016, Rationally engineered Cas9 nucleases with improved specificity, Science, 351, 84, 10.1126/science.aad5227
Spranger, 2013, Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8+ T cells, Sci. Transl. Med., 5, 200ra116, 10.1126/scitranslmed.3006504
Strome, 2003, B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma, Cancer Res., 63, 6501
Stromnes, 2015, T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma, Cancer Cell, 28, 638, 10.1016/j.ccell.2015.09.022
Suarez, 2016, Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model, Oncotarget, 7, 34341, 10.18632/oncotarget.9114
Suzuki, 2013, Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence, J. Clin. Oncol., 31, 490, 10.1200/JCO.2012.45.2052
Tang, 2018, PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression, J. Clin. Invest., 128, 580, 10.1172/JCI96061
Tano, 2018, An ex-vivo patient-derived, immunocompetent (PDI) culture system to evaluate immunotherapeutic agents' anti-tumor efficacy, J. Thorac. Oncol., 13, S376, 10.1016/j.jtho.2018.08.362
Tanoue, 2017, Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors, Cancer Res., 77, 2040, 10.1158/0008-5472.CAN-16-1577
Taube, 2012, Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, Sci. Transl. Med., 4, 127ra137, 10.1126/scitranslmed.3003689
Taube, 2015, Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade, Clin. Cancer Res., 21, 3969, 10.1158/1078-0432.CCR-15-0244
Tivol, 1995, Loss of Ctla-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of Ctla-4, Immunity, 3, 541, 10.1016/1074-7613(95)90125-6
Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med., 366, 2443, 10.1056/NEJMoa1200690
Tsai, 2015, GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases, Nat. Biotechnol., 33, 187, 10.1038/nbt.3117
Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954
Wang, 2014, Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity, Cancer Immunol. Res., 2, 154, 10.1158/2326-6066.CIR-13-0027
Wilkie, 2012, Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling, J. Clin. Immunol., 32, 1059, 10.1007/s10875-012-9689-9
Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N. Engl. J. Med., 369, 122, 10.1056/NEJMoa1302369
Yang, 2018, Targeting VEGF/VEGFR to modulate antitumor immunity, Front. Immunol., 9, 978, 10.3389/fimmu.2018.00978
Zappasodi, 2018, Emerging concepts for immune checkpoint blockade-based combination therapies, Cancer Cell, 34, 690, 10.1016/j.ccell.2018.09.008
Zhang, 2003, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer, N. Engl. J. Med., 348, 203, 10.1056/NEJMoa020177